Improving lower urinary tract symptoms in BPH.

Area of Science:

• Urology
• Geriatric Medicine
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is highly prevalent in aging men, affecting over 60% of those in their sixties.
• Lower urinary tract symptoms (LUTS) associated with BPH impact over 40% of men in this age group, increasing with age.
• Symptomatic BPH often progresses, leading to surgical intervention for approximately 20% of patients, while others initially undergo active surveillance.

Purpose of the Study:

• To review the medical management of benign prostatic hyperplasia (BPH).
• To compare the efficacy of monotherapy versus combination therapy for BPH symptom relief and disease progression.
• To outline evidence-based treatment approaches for varying symptom severity.

Main Methods:

• Review of evidence-based medical management strategies for BPH.
• Analysis of alpha1-blockers and 5-alpha-reductase inhibitors (5-ARIs) as primary treatments.
• Evaluation of combination therapy efficacy against monotherapy.

Main Results:

• Alpha1-blockers and 5-ARIs are the two main evidence-based medical treatments for moderate BPH symptoms.
• Combination therapy with an alpha1-blocker and a 5-ARI demonstrates greater effectiveness than monotherapy.
• Combination therapy improves symptom relief and prevents disease progression more effectively than individual drug treatments.

Conclusions:

• Combination therapy is more effective than monotherapy for managing benign prostatic hyperplasia (BPH) symptoms and slowing progression.
• Medical management, including alpha1-blockers and 5-ARIs, is suitable for most patients with moderate to severe BPH.
• Active surveillance remains appropriate for mild symptoms, but progression necessitates treatment.